LEIDEN JEFFREY M 4

What Happened
Jeffrey M. Leiden, Executive Chairman and Director of Vertex Pharmaceuticals (VRTX), was reported as receiving 9,012 shares as an award on 01/22/2026. The transaction is recorded as an award/grant (code A) at $0.00 per share (reported acquisition value $0). This was a compensation award (performance shares), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (appears filed within the normal 2-business-day Form 4 window).
• Security and amount: 9,012 shares acquired as an award; reported price $0.00; reported total $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: These are earned performance shares tied to a performance stock unit award granted 02/12/2025. The compensation committee certified performance attainment on 01/22/2026; the shares are scheduled to vest on 02/24/2026.

Context

• This transaction reflects compensation tied to previously granted performance stock units that met their performance conditions. Such awards are routine executive compensation and do not necessarily signal a new trading decision or market view.
• Because the shares are performance-vested and have a future vesting date, they may still be subject to transfer restrictions until vesting.